{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:10:25Z","timestamp":1769580625698,"version":"3.49.0"},"reference-count":28,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney Blood Press Res"],"abstract":"<jats:p>Introduction: We previously reported the efficacy and safety of low-dose (12.5 mg\/day) spironolactone for chronic kidney disease (CKD) with diabetes. Few studies have examined the characteristics of patients who may have reduced urinary albumin-creatinine ratio (UACR) on mineralocorticoid receptor antagonists. In this study, we aimed to identify the clinical characteristics of patients prone to benefit from UACR reduction with low-dose spironolactone. Methods: This was a post hoc analysis of a previous trial and included 55 patients assigned to the spironolactone group. Univariate regression analysis was performed to determine the association between the change in UACR after 24 weeks of low-dose spironolactone administration and baseline exploratory parameters. Multiple regression analysis was conducted on the associated parameters, and regression models were created for analysis. A similar analysis was performed for changes in serum potassium levels and estimated glomerular filtration rate (eGFR) after 24 weeks of spironolactone administration. Results: In the univariate analysis, baseline UACR, triglyceride levels, and eGFR were associated with changes in UACR. The regression coefficient estimates were significant for baseline UACR, triglyceride levels, and eGFR (p = 0.002, 0.017, and 0.003, respectively). The reduction in UACR was greater with higher baseline UACR and triglyceride levels, and lower baseline eGFRs. The increase in serum potassium levels due to low-dose spironolactone administration showed a negative correlation with baseline serum potassium levels and no correlation with baseline eGFR, suggesting its safety. Conclusions: It may not be too late to start treatment with low-dose spironolactone, even in patients with relatively advanced CKD with diabetes.<\/jats:p>","DOI":"10.1159\/000549942","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:00:36Z","timestamp":1765731636000},"page":"50-60","source":"Crossref","is-referenced-by-count":0,"title":["Factors Influencing the Efficacy of Low-Dose Spironolactone in Adults with Chronic Kidney Disease and Type 2 Diabetes: A post hoc Analysis"],"prefix":"10.1159","volume":"51","author":[{"given":"Shohei","family":"Takayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7765-9466","authenticated-orcid":false,"given":"Ako","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Koinuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiji","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Hiwatashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhisa","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200109203451215"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.12.057"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(97)00166-4"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070688"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad144"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy217"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2331"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50007"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.508"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac157"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.040"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000368470"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.06.019"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000044937.95080.e9"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7549.1080"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000093221"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1023"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12629"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001854"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0944"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.095489"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft281"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.539122"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw406"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283638b1a"}],"container-title":["Kidney and Blood Pressure Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000549942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:02:27Z","timestamp":1769533347000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000549942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000549942","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.30880076","asserted-by":"subject"}]},"ISSN":["1420-4096","1423-0143"],"issn-type":[{"value":"1420-4096","type":"print"},{"value":"1423-0143","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]}}}